Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 19, issue 6, 2021

Towards a New Understanding of Unmet Medical Need pp. 785-788

Kyann Zhang, Gayathri Kumar and Chris Skedgel

Methodological Note: Reporting Deterministic versus Probabilistic Results of Markov, Partitioned Survival and Other Non-Linear Models pp. 789-795

Edward C. F. Wilson

How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England pp. 797-810

Caroline S. Clarke, Cecilia Vindrola-Padros, Claire Levermore, Angus I. G. Ramsay, Georgia B. Black, Kathy Pritchard-Jones, John Hines, Gillian Smith, Axel Bex, Muntzer Mughal, David Shackley, Mariya Melnychuk, Steve Morris, Naomi J. Fulop and Rachael M. Hunter

National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India pp. 811-823

Shankar Prinja, Yashika Chugh, Kavitha Rajsekar and V. R. Muraleedharan

Systematic Literature Review of Guidelines on Budget Impact Analysis for Health Technology Assessment pp. 825-838

Yashika Chugh, Maria Francesco and Shankar Prinja

Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis pp. 839-855

Leila Doshmangir, Edris Hasanpoor, Gerard Abou Jaoude, Behzad Eshtiagh and Hassan Haghparast-Bidgoli

The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review pp. 857-869

Emily Leckenby, Dalia Dawoud, Jacoline Bouvy and Páll Jónsson

COVID-19 Vaccine Demand and Financial Incentives pp. 871-883

Carlos Carpio, Ioana A. Coman, Oscar Sarasty and Manuel García

How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13 pp. 885-903

Stephen Martin, James Lomas, Karl Claxton and Francesco Longo

EQ-5D-5L Health-State Values for the Mexican Population pp. 905-914

Cristina Gutierrez-Delgado, Rosa-María Galindo-Suárez, Cesar Cruz-Santiago, Koonal Shah, Manny Papadimitropoulos, Yan Feng, Bernarda Zamora Talaya and Nancy Devlin

Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe pp. 915-927

Luka Vončina, Tea Strbad, Jurij Fürst, Maria Dimitrova, Maria Kamusheva, Megi Vila, Ileana Mardare, Kristina Hristova, Andras Harsanyi, Dragana Atanasijević, Igor Banović and Ana Bobinac

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting pp. 929-940

B. Muresan, C. Mamolo, J. C. Cappelleri, M. J. Postma and B. Heeg

The Health and Productivity Burden of Depression in South Korea pp. 941-951

Ella Zomer, YongJoo Rhee, Danny Liew and Zanfina Ademi

Correction to: Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta‑analysis pp. 953-953

Leila Doshmangir, Edris Hasanpoor, Gerard Abou Jaoude, Behzad Eshtiagh and Hassan Haghparast-Bidgoli

Volume 19, issue 5, 2021

Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies pp. 625-634

Jennifer G. Gaultney, Jacoline C. Bouvy, Richard H. Chapman, Alexander J. Upton, Stacey Kowal, Carsten Bokemeyer, Oriol Solà-Morales, Jürgen Wolf and Andrew H. Briggs

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere? pp. 635-644

Patricia Cubi-Molla, Martin Buxton and Nancy Devlin

A Review of Web-Based Tools for Value-of-Information Analysis pp. 645-651

Haitham Tuffaha, Claire Rothery, Natalia Kunst, Chris Jackson, Mark Strong and Stephen Birch

‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions pp. 653-664

Rhiannon Tudor Edwards and Catherine Louise Lawrence

The PLASMA System for Transurethral Resection of the Prostate: A NICE Medical Technologies Guidance Update pp. 665-672

Laura Knight, Susan Peirce and Rhys Morris

A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks pp. 673-697

Janetta E. Skarp, Laura E. Downey, Julius W. E. Ohrnberger, Lucia Cilloni, Alexandra B. Hogan, Abagael L. Sykes, Susannah S. Wang, Hiral Anil Shah, Mimi Xiao and Katharina Hauck

Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines pp. 699-708

Christian Alvin H. Buhat, Destiny S. M. Lutero, Yancee H. Olave, Kemuel M. Quindala, Mary Grace P. Recreo, Dylan Antonio S. J. Talabis, Monica C. Torres, Jerrold M. Tubay and Jomar F. Rabajante

How Much Money Should be Paid for a Patient to Isolate During the COVID-19 Outbreak? A Discrete Choice Experiment in Iran pp. 709-719

Enayatollah Homaie Rad, Mohammad Hajizadeh, Vahid Yazdi-Feyzabadi, Sajad Delavari and Zahra Mohtasham-Amiri

The Impact of Financing Health Services on Income Inequality in an Unequal Society: The Case of South Africa pp. 721-733

John E. Ataguba

Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom pp. 735-745

Han Geul Byun, Minyoung Jang, Hyun Kyeong Yoo, James Potter and Taek Sang Kwon

Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study pp. 747-756

Victoria K. Brennan, Georgina Jones, Stephen Radley and Simon Dixon

Consumers' Preferences and Willingness to Pay for Personalised Nutrition pp. 757-767

Daniel Pérez-Troncoso, David Epstein and José A. Castañeda-García

Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data pp. 769-782

Jeetendra Yadav, Geetha R. Menon and Denny John

Comment on: “Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data” pp. 783-784

Nafis Faizi and Yasir Alvi

Volume 19, issue 4, 2021

Cost of Medicare for All: Review of the Estimates pp. 453-461

John A. Nyman

Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines pp. 463-472

Chris Painter, Wanrudee Isaranuwatchai, Juthamas Prawjaeng, Hwee Lin Wee, Brandon Wen Bing Chua, Vinh Anh Huynh, Jing Lou, Fang Ting Goh, Nantasit Luangasanatip, Wirichada Pan-Ngum, Wang Yi, Hannah Clapham and Yot Teerawattananon

Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations pp. 473-486

M. Cochrane, E. Mitchell, W. Hollingworth, E. Crawley and D. Trépel

Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review pp. 487-499

Patrick R. LaFontaine, Jing Yuan, Katherine M. Prioli, Priti Shah, Jay H. Herman and Laura T. Pizzi

Costs of Illness of Spinal Muscular Atrophy: A Systematic Review pp. 501-520

Erik Landfeldt, Astrid Pechmann, Hugh J. McMillan, Hanns Lochmüller and Thomas Sejersen

Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom pp. 521-535

James Buchanan, Laurence Roope, Liz Morrell, Koen B. Pouwels, Julie V. Robotham, Lucy Abel, Derrick W. Crook, Tim Peto, Christopher C. Butler, A. Sarah Walker and Sarah Wordsworth

Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis pp. 537-544

George Dranitsaris, Carlo DeAngelis, Blake Pearson, Laura McDermott and Bernd Pohlmann-Eden

Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea pp. 545-555

Siin Kim, Sola Han, Hyungtae Kim and Hae Sun Suh

The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil pp. 557-577

Wânia Cristina Silva, Brian Godman, Francisco Acúrcio, Mariângela Leal Cherchiglia, Antony Martin, Konrad Maruszczyk, Jans Bastos Izidoro, Marcos André Portella, Agner Pereira Lana, Orozimbo Henriques Campos Neto and Eli Iola Gurgel Andrade

The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data pp. 579-591

Cathrine Elgaard Jensen, Sabrina Storgaard Sørensen, Claire Gudex, Morten Jensen, Kjeld Møller Pedersen and Lars Holger Ehlers

Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease pp. 593-604

Tomas Mlcoch, Barbora Decker and Tomas Dolezal

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives pp. 605-618

Jingyan Yang, Rongzhe Liu, Varun Ektare, Jennifer Stephens and Ahmed Shelbaya

Comment on: “Willingness to Pay for a COVID-19 Vaccine” pp. 619-621

Philipp Sprengholz and Cornelia Betsch

Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine” pp. 623-624

Leidy Garcia and Arcadio A. Cerda

Volume 19, issue 3, 2021

Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries pp. 281-304

Yitong Wang, Tingting Qiu, Junwen Zhou, Clément Francois and Mondher Toumi

Copula Models for Addressing Sample Selection in the Evaluation of Public Health Programmes: An Application to the Leeds Let’s Get Active Study pp. 305-312

Paolo Candio, Andrew J. Hill, Stavros Poupakis, Anni-Maria Pulkki-Brännström, Chris Bojke and Manuel Gomes

The Cost-Effectiveness of Pulmonary Rehabilitation for COPD in Different Settings: A Systematic Review pp. 313-324

Shengnan Liu, Qiheng Zhao, Wenshuo Li, Xuetong Zhao and Kun Li

The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review pp. 325-341

Nicolas Iragorri, Claire Oliveira, Natalie Fitzgerald and Beverley Essue

Willingness to Pay for a COVID-19 Vaccine pp. 343-351

Arcadio A. Cerda and Leidy Garcia

Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme pp. 353-370

Shankar Prinja, Maninder Pal Singh, Kavitha Rajsekar, Oshima Sachin, Praveen Gedam, Anu Nagar and Balram Bhargava

Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C pp. 371-387

Pingyu Chen, Min Jin, Yang Cao and Hongchao Li

What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches pp. 389-401

Anthony J. Hatswell, Ash Bullement, Michael Schlichting and Murtuza Bharmal

Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis pp. 403-414

Trevor A. Ellison, Samantha Clark, Jonathan C. Hong, Kevin D. Frick and Dorry L. Segev

Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions pp. 415-428

Orgul Ozturk, Yuan Hong, Suzanne McDermott and Margaret Turk

Management of Chest Indrawing Pneumonia in Children Under Five Years at the Outpatient Health Facilities in Nigeria: An Economic Evaluation pp. 429-437

Charles E. Okafor

Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies pp. 439-450

Sun-Hong Kwon, Hea-Sun Park, Young-Jin Na, Chul Park, Ju-Young Shin and Hye-Lin Kim

Correction to: Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India’s National Publicly Financed Health Insurance Scheme pp. 451-451

Shankar Prinja, Maninder Pal Singh, Kavitha Rajsekar, Oshima Sachin, Praveen Gedam, Anu Nagar and Balram Bhargava

Volume 19, issue 2, 2021

The Vatican City State Internal Healthcare System Response to COVID-19 Pandemic: Prevention and Control Strategies pp. 141-144

Andrea Arcangeli, Massimo Ralli, Fabio De-Giorgio, Paolo Maurizio Soave and Lucia Ercoli

Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance pp. 145-153

Susan O’Connell, Megan Dale, Helen Morgan, Kimberley Carter and Grace Carolan-Rees

Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review pp. 155-162

William V. Padula, Hui-Han Chen and Charles E. Phelps

The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations pp. 163-180

Fei Yang, Meixia Liao, Pusheng Wang, Zheng Yang and Yongguang Liu

How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany pp. 181-190

Afschin Gandjour

French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30 pp. 191-202

Virginie Nerich, Eva Maria Gamper, Richard Norman, Madeleine King, Bernhard Holzner, Rosalie Viney and Georg Kemmler

Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD pp. 203-215

Kate M. Johnson, Mohsen Sadatsafavi, Amin Adibi, Larry Lynd, Mark Harrison, Hamid Tavakoli, Don D. Sin and Stirling Bryan

Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment pp. 217-229

Mujaheed Shaikh, Pietro Giudice and Dimitrios Kourouklis

Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections pp. 231-241

Ann T. MacIntyre, Alex Hirst, Radha Duttagupta, Desiree Hollemon, David K. Hong and Timothy A. Blauwkamp

Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK pp. 243-252

Rucha Vadia and Tom Stargardt

Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment pp. 253-266

Rakhee Raghunandan, Kirsten Howard, Carlo A. Marra, June Tordoff and Alesha Smith

Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme pp. 267-277

Beena Joshi, Kusum V. Moray, Oshima Sachin, Himanshu Chaurasia and Shahina Begum

Correction to: Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme pp. 279-279

Beena Joshi, Kusum V. Moray, Oshima Sachin, Himanshu Chaurasia and Shahina Begum

Volume 19, issue 1, 2021

Economic Theory and Medical Assistance in Dying pp. 5-8

Donald A. Redelmeier and Allan S. Detsky

Using a Formal Strategy of Priority Setting to Mitigate Austerity Effects Through Gains in Value: The Role of Program Budgeting and Marginal Analysis (PBMA) in the Brazilian Public Healthcare System pp. 9-15

Brayan V. Seixas and Craig Mitton

Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions pp. 17-27

Dina Jankovic, Laura Bojke, David Marshall, Pedro Saramago Goncalves, Rachel Churchill, Hollie Melton, Sally Brabyn and Lina Gega

Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results pp. 29-44

Ru Han, Clément François and Mondher Toumi

Elections have Consequences: Partisan Politics may be Literally Killing Us pp. 45-56

Alexander Maas and Liang Lu

Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator pp. 57-68

Moritz Hadwiger, Fabian-Simon Frielitz, Nora Eisemann, Christian Elsner, Nikolaos Dagres, Gerhard Hindricks and Alexander Katalinic

Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus pp. 69-79

Shanshan Hu, Xun Deng, Yanjiao Ma, Zhilei Li, Yuhang Wang and Yong Wang

Availability and Variability of Consumer Prices for Lumbar Discectomy Across US Hospitals in 2018 pp. 81-96

Alexander J. Butler, Caroline J. Granger, Sebastian Rivera, Chester J. Donnally, Alexander Ghasem, Deborah Li and Michael Y. Wang

Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer pp. 97-109

Julia Simoes Correa-Galendi, Maria Pilar Estevez Diz, Stephanie Stock and Dirk Müller

Using Eye-Tracking Technology with Older People in Memory Clinics to Investigate the Impact of Mild Cognitive Impairment on Choices for EQ-5D-5L Health States Preferences pp. 111-121

Kaiying Wang, Chris Barr, Richard Norman, Stacey George, Craig Whitehead and Julie Ratcliffe

Economic Evaluation of Senshio® (Ospemifene) for the Treatment of Vulvovaginal Atrophy in Scotland pp. 123-132

Amy Dymond, Hayden Holmes, Jessica McMaster, Joyce Craig, Heather Davies, Stuart Mealing and Rodolphe Perard

Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland pp. 133-140

Amelia Smith, Stephen Doran, Maria Daly, Cormac Kennedy and Michael Barry